New diabetes drug HM11260C aims to lower blood sugar in phase 3 trial

NCT ID NCT07379333

Recruiting now Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests an experimental drug called HM11260C in adults with type 2 diabetes whose blood sugar is not well controlled with metformin and dapagliflozin. About 118 participants will receive either HM11260C or a placebo, and researchers will measure changes in HbA1c (a key blood sugar marker) over 36 weeks. The goal is to see if this new drug can safely improve blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HM11260C (an experimental drug for diabetes)
What this could lead to: If successful, this could provide a new treatment option for people with type 2 diabetes who need better blood sugar control.
What could go wrong: This is still an experimental drug in a relatively small Phase 3 trial. It may not prove more effective than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

The Catholic University of Korea Bucheon St. Mary's Hospital
RECRUITING

Gyeonggi-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.